Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
Kensei YamaguchiKazumasa FujitaniFumio NagashimaYasushi OmuroNozomu MachidaTomohiro NishinaToshiko KoueMika TsujimotoKaijiro MaedaTaroh SatohPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2018)
These findings suggest that ramucirumab monotherapy has clinical activity and a manageable safety profile in Japanese patients with gastric cancer after disease progression following first-line chemotherapy.